NVYT.F Stock Overview
Provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Novacyt S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.50 |
| 52 Week High | €0.83 |
| 52 Week Low | €0.50 |
| Beta | -1.8 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0.20% |
| 3 Year Change | -91.49% |
| 5 Year Change | n/a |
| Change since IPO | -45.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVYT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.07% | -0.2% |
| 1Y | 0.2% | 6.9% | 28.2% |
Return vs Industry: NVYT.F underperformed the US Biotechs industry which returned 6.9% over the past year.
Return vs Market: NVYT.F underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| NVYT.F volatility | |
|---|---|
| NVYT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NVYT.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NVYT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 120 | Lyn Rees | www.novacyt.com |
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.
Novacyt S.A. Fundamentals Summary
| NVYT.F fundamental statistics | |
|---|---|
| Market cap | US$55.80m |
| Earnings (TTM) | -US$32.19m |
| Revenue (TTM) | US$10.02m |
5.6x
P/S Ratio-1.7x
P/E RatioIs NVYT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVYT.F income statement (TTM) | |
|---|---|
| Revenue | UK£7.87m |
| Cost of Revenue | UK£4.84m |
| Gross Profit | UK£3.03m |
| Other Expenses | UK£28.33m |
| Earnings | -UK£25.30m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 38.51% |
| Net Profit Margin | -321.40% |
| Debt/Equity Ratio | 0% |
How did NVYT.F perform over the long term?
See historical performance and comparison